NASDAQ · Biotechnology

NuCana plc (NCNA) Stock

$1.35 +3.05% NASDAQ: NCNA Healthcare

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform.

Valuation

MetricValue
Price$1.35
Market Cap$8.20M
P/E Ratio-0.14
P/B Ratio0.16
P/S Ratio0.00
EPS (TTM)$-7.75
52-Week High$13.00
52-Week Low$1.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-153.80%
ROA-111.58%
ROCE-93.95%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.03
Current Ratio5.48

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-45.0M$-44.0M$-33.0M$-23.0M$-20.0M
Net Profit$-41.0M$-32.0M$-28.0M$-19.0M$-29.0M
EPS$-9.75$-6.12$-5.25$-3.27$-7.75
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$77.0M$58.0M$28.0M$15.0M$30.0M
Total Liabilities$12.0M$20.0M$13.0M$9.0M$6.0M
Cash$60.0M$42.0M$17.0M$7.0M$24.0M
Borrowings$0$1.0M$0$0$1.0M

Latest News

European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading MT Newswires · Jul 20, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT Newswires · Jul 6, 2026 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading MT Newswires · Jul 2, 2026 European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading MT Newswires · Jul 1, 2026 European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-23.0M$-26.0M$-19.0M$-7.0M
Investing Cash Flow$-5.0M$0$2.0M$0$0
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$-27.0M$-18.0M$-25.0M$-10.0M$18.0M
Free Cash Flow$-25.0M$-24.0M$-27.0M$-19.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.66
FCF Yield-128.26%
Quick Ratio5.48
Interest Coverage0.00
Return 1Y-86.50%
Return 3Y-99.97%
Return 5Y-99.99%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CASICASI Pharmaceuticals, Inc. $0.15 +3.08% -0.07 $2.33M 0.00%
CLGN $0.27 -9.04% -0.48 $3.54M 0.00%
CLSDClearside Biomedical, Inc. $0.41 +0.00% -0.11 $2.15M 0.00%
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
GDTC $0.93 -5.99% -4.00 $11.01M 0.00%

About NuCana plc

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.

NuCana plc is headquartered in GB.

NuCana plc (NCNA) stock trades at $1.35 with a market capitalization of $8.20M. The stock is valued at a price-to-earnings (P/E) ratio of -0.14, price-to-book of 0.16, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.21 and $13.00, and currently trades 89.6% below its 52-week high.

On profitability, NuCana plc generates a return on equity (ROE) of -153.80%, return on capital employed of -93.95%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.nucana.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides